-
公开(公告)号：US12091460B2
公开(公告)日：2024-09-17
申请号：US16906634
申请日：2020-06-19
CPC分类号： C07K16/2809 , A61B6/037 , A61B6/481 , A61K51/1042 , C07K16/2878 , C07K16/3092 , A61K2039/507 , C07K2317/31 , C07K2317/75
摘要： Provided herein are method of treating cancer using bispecific antigen-binding molecules that bind to Mucin 16 (MUC16) and CD3. According to certain embodiments, the antibodies useful herein bind human MUC16 with high affinity and bind CD3 to induce human T cell proliferation. According to certain embodiments, bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human MUC16 are particularly useful herein. In certain embodiments, the bispecific antigen-binding molecules in combination with an anti-4-1BB agonist are capable of inhibiting the growth of tumors expressing MUC16, for example, ovarian tumors. The bispecific antigen-binding molecules in combination with an anti-4-1BB agonist are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial, for example, in the treatment of various cancers.
-
公开(公告)号：US12077779B2
公开(公告)日：2024-09-03
申请号：US16349225
申请日：2017-11-10
发明人： Tai Gyu Kim , Hyun Jung Sohn , Hyun Woo Cho , Su Yeon Kim
IPC分类号： A61K48/00 , A61K35/17 , A61K39/39 , A61K51/10 , C07K14/705 , C12N5/073 , C12N5/0783 , C12N5/09 , C12N5/10 , G01N33/50 , G01N33/569
CPC分类号： C12N5/0638 , A61K35/17 , A61K39/39 , A61K51/1042 , C07K14/70532 , C07K14/70578 , C07K14/70596 , C12N5/0603 , C12N5/0636 , C12N5/0694 , C12N5/10 , G01N33/505 , G01N33/56972 , C12N2501/2302 , C12N2501/51 , C12N2501/515 , C12N2501/52 , C12N2510/00
摘要： The present invention relates to a novel feeder cell and a method for growing gamma delta T cells using the same. More specifically, a large amount of gamma delta T cells may be grown in vitro with high purity and without simulation of a T cell receptor by using a feeder cell into which costimulatory molecules are introduced and a low concentration of IL-2, differentiation into central memory cells may be possible when stimulated, activity by the feeder cell, and cytolytic against tumour cells is provided.
-
公开(公告)号：US20180009892A1
公开(公告)日：2018-01-11
申请号：US15654514
申请日：2017-07-19
CPC分类号： C07K16/2803 , A61K38/05 , A61K47/6817 , A61K47/6851 , A61K47/6881 , A61K51/1027 , A61K51/1042 , A61K51/1096 , A61K2039/505 , A61P35/00 , A61P35/02 , C07K16/005 , C07K16/2809 , C07K16/30 , C07K2317/14 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2319/00 , G01N33/57492 , G01N2333/912
摘要： The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for Receptor tyrosine kinase-like Orphan Receptors (ROR), and to uses thereof, for example in the treatment of cancer. The invention extends to polynucleotide and polypeptide sequences encoding the antibodies, and therapeutic uses thereof, and to diagnostic kits comprising these molecules. The invention also extends to antibody-drug conjugates and to uses thereof in therapy.
-
公开(公告)号：US20230211024A1
公开(公告)日：2023-07-06
申请号：US17782132
申请日：2020-12-03
申请人： ImaginAb, Inc.
CPC分类号： A61K51/1042 , A61B6/037 , A61K51/1045 , A61K2039/505
摘要： Methods of non-invasively imaging a subject using two or more antigen-binding constructs that selectively bind to immune cell markers are described.
-
公开(公告)号：US20180142016A1
公开(公告)日：2018-05-24
申请号：US15574810
申请日：2016-05-17
发明人： Brian WONG , Emma MASTELLER , Cheng LIU , Yiyang XU , Hong LIU , Su YAN , Jingyi XIANG , Pei WANG
IPC分类号： C07K16/28 , A61K47/68 , A61K51/10 , A61P35/00 , A61K38/05 , A61P35/02 , G01N33/574 , C07K16/00
CPC分类号： C07K16/2803 , A61K38/05 , A61K47/6817 , A61K47/6851 , A61K47/6881 , A61K51/1027 , A61K51/1042 , A61K51/1096 , A61K2039/505 , A61P35/00 , A61P35/02 , C07K16/005 , C07K16/2809 , C07K16/30 , C07K2317/14 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2319/00 , G01N33/57492 , G01N2333/912
摘要： The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for Receptor tyrosine kinase-like Orphan Receptors (ROR), and to uses thereof, for example in the treatment of cancer. The invention extends to polynucleotide and polypeptide sequences encoding the antibodies, and therapeutic uses thereof, and to diagnostic kits comprising these molecules. The invention also extends to antibody-drug conjugates and to uses thereof in therapy.
-
公开(公告)号：US07220399B2
公开(公告)日：2007-05-22
申请号：US10724397
申请日：2003-12-01
CPC分类号： B82Y5/00 , A61K47/6893 , A61K51/1042 , A61K51/1045 , A61K51/1096
摘要： The present invention relates to radioimmunoconjugates useful in targeted radioimmunotherapy and methods of treating a patient using radioimmunoconjugates. The radioimmunoconjugates of the present invention comprise an alpha- or beta-emitting radioisotope and a binding site linked to or on an antigen-binding fragment of an antibody which specifically binds to a tumor-associated antigen. The methods of treating a patient can include administering one or more clearing agents to the patient in conjunction with the radioimmunoconjugate of the present invention, as well as subsequently grafting bone-marrow or autologous stem-cells to the patient.
摘要翻译： 本发明涉及可用于靶向放射免疫治疗的放射免疫缀合物和使用放射免疫缀合物治疗患者的方法。 本发明的放射免疫缀合物包含α或β发射放射性同位素和与特异性结合肿瘤相关抗原的抗体的抗原结合片段连接或连接的结合位点。 治疗患者的方法可以包括与本发明的放射免疫缀合物一起给予患者一种或多种清除剂，以及随后将骨髓或自体干细胞移植到患者体内。
-
公开(公告)号：US20240209086A1
公开(公告)日：2024-06-27
申请号：US18524083
申请日：2023-11-30
申请人： PETMEDIX LTD.
CPC分类号： C07K16/2809 , A61K47/6803 , A61K47/6849 , A61K47/6913 , A61K47/6929 , A61K51/1027 , A61K51/1042 , A61P35/00 , C07K16/2887 , G01N33/6872 , A61K2039/505 , C07K2317/31 , C07K2317/622 , C07K2317/92 , G01N2333/7051 , G01N2333/70596
摘要： This disclosure provides a bispecific canine antigen-binding molecule comprising a first antigen binding domain or antigen-binding portion thereof that specifically binds canine CD3, and a second antigen binding domain or antigen-binding portion thereof that specifically binds canine CD20, compositions comprising the same, and methods of their use. The disclosure also provides a canine antibody or antigen-binding portion thereof that binds canine CD3, compositions comprising the same, and methods of their use. The disclosure also provides a canine antibody or antigen-binding portion thereof that binds canine CD20, compositions comprising the same, and methods of their use.
-
公开(公告)号：US20040180001A1
公开(公告)日：2004-09-16
申请号：US10724397
申请日：2003-12-01
IPC分类号： A61K051/00
CPC分类号： B82Y5/00 , A61K47/6893 , A61K51/1042 , A61K51/1045 , A61K51/1096
摘要： The present invention relates to radioimmunoconjugates useful in targeted radioimmunotherapy and methods of treating a patient using radioimmunoconjugates. The radioimmunoconjugates of the present invention comprise an alpha- or beta-emitting radioisotope and a binding site linked to or on an antigen-binding fragment of an antibody which specifically binds to a tumor-associated antigen. The methods of treating a patient can include administering one or more clearing agents to the patient in conjunction with the radioimmunoconjugate of the present invention, as well as subsequently grafting bone-marrow or autologous stem-cells to the patient.
摘要翻译： 本发明涉及可用于靶向放射免疫治疗的放射免疫缀合物和使用放射免疫缀合物治疗患者的方法。 本发明的放射免疫缀合物包含α或β发射放射性同位素和与特异性结合肿瘤相关抗原的抗体的抗原结合片段连接或连接的结合位点。 治疗患者的方法可以包括与本发明的放射免疫缀合物一起给予患者一种或多种清除剂，以及随后将骨髓或自体干细胞移植到患者体内。
-
公开(公告)号：US06667024B1
公开(公告)日：2003-12-23
申请号：US09588565
申请日：2000-06-07
IPC分类号： A61K5100
CPC分类号： B82Y5/00 , A61K47/6893 , A61K51/1042 , A61K51/1045 , A61K51/1096
摘要： The present invention relates to radioimmunoconjugates useful in targeted radioimmunotherapy and methods of treating a patient using radioimmunoconjugates. The radioimmunoconjugates of the present invention comprise an alpha- or beta-emitting radioisotope and a binding site linked to or on an antigen-binding fragment of an antibody which specifically binds to a tumor-associated antigen. The methods of treating a patient can include administering one or more clearing agents to the patient in conjunction with the radioimmunoconjugate of the present invention, as well as subsequently grafting bone-marrow or autologous stem-cells to the patient.
摘要翻译： 本发明涉及可用于靶向放射免疫治疗的放射免疫缀合物和使用放射免疫缀合物治疗患者的方法。 本发明的放射免疫缀合物包含α或β发射放射性同位素和与特异性结合肿瘤相关抗原的抗体的抗原结合片段连接或连接的结合位点。 治疗患者的方法可以包括与本发明的放射免疫缀合物一起给予患者一种或多种清除剂，以及随后将骨髓或自体干细胞移植到患者体内。
-
10.发明申请公开(公告)号：US20190218290A1
公开(公告)日：2019-07-18
申请号：US16331449
申请日：2017-09-07
CPC分类号： C07K16/2809 , A61K47/6849 , A61K49/0058 , A61K51/1042 , C07K2317/14 , C07K2317/22 , C07K2317/569 , G01N33/6872
摘要： The present invention relates to variable domains of camelid heavy-chain antibodies (VHH domains) directed against the human CD3ε component of the T cell receptor and specifically to methods of use of said polypeptides for delivering prophylactic, therapeutic or diagnostic compounds to human T lymphocytes. It further describes a novel one-step method for the identification of phage displayed camel monoclonal antibodies.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.015 秒)
